Clinical trials: terminated
Cancer Disease
PSMA/CD70 Bi-specific CAR-T Cell Therapy
The purpose of this study is to assess the feasibility, safety and efficacy of anti-PSMA/CD70 bi-specific CAR-T cell therapy in patients with CD70 and PSMA positive malignancies.
- Trial name
- NCT05437341
- Testing
- bi-4SCAR PSMA/CD70 T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Angelman Syndrome
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
The main goal of the study is to evaluate the safety and efficacy of GTX-102 in participants with Angelman syndrome.
- Trial name
- Aurora (NCT07157254)
- Testing
- No intervention, GTX-102
- Where
- 21 sites in United States, Argentina and 6 more
- Volunteers
- 55 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Atopic Dermatitis
Dupilumab De-escalation in Pediatric Atopic Dermatitis
This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD)…
- Trial name
- NCT06116526
- Testing
- Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Angelman Syndrome
Long-term Extension of GTX-102 in Angelman Syndrome
The primary objective of the study is to evaluate the long-term safety profile of GTX-102 in participants with Angelman Syndrome (AS)
- Trial name
- NCT06415344
- Testing
- GTX-102
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 66 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Cancers Which Are CD44v6 Positive
4SCAR-CD44v6 T Cell Therapy Targeting Cancer
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of 4SCAR-CD44v6 T-cell therapy targeting multiple cancers.
- Trial name
- NCT04427449
- Testing
- CD44v6-specific CAR gene-engineered T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Angelman Syndrome
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with deletion-type Angelman Syndrome (AS).
- Trial name
- Aspire (NCT06617429)
- Testing
- GTX-102
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 129 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
T-Cell Acute Lymphoblastic Leukemia
NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
The purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of T-cell acute lymphoblastic leukemia (T-ALL): multi-antigen-targeted chimeric antigen receptor T cells…
- Trial name
- NCT05277753
- Testing
- Antigen-specific T cells CAR-T/CTL and DCvac
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Ovarian Cancer
Engineered Immune Effectors Against Ovarian Cancer
This is a single-arm, open-label, phase I/II trial to evaluate the safety and efficacy of ovarian cancer specific cytotoxic lymphocytes (OC-CTLs) in women.
- Trial name
- NCT03362606
- Testing
- OC-CTLs
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Treat and Prevent Covid-19 Infection
Safety and Immunity of Covid-19 aAPC Vaccine
In December 2019, viral pneumonia (Covid-19) caused by a novel beta-coronavirus (SARS-CoV-2) broke out in Wuhan, China. Some patients rapidly progressed and suffered severe acute respiratory failure and died, making it imperative…
- Trial name
- NCT04299724
- Testing
- Pathogen-specific aAPC
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Cervical Cancer
Engineered Immune Effectors Against Cervical Cancer
The primary objective of this study is to evaluate the safety of cervical cancer specific engineered immune effectors (CC-EIEs).
- Trial name
- NCT03362619
- Testing
- CC-EIEs
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
B Cell Malignancies
CD19/79b Bi-specific CAR-T Cell Therapy
The purpose of this study is to assess the feasibility, safety and efficacy of CD19/79b bi-specific CAR-T cell therapy in patients with CD19 and/or CD79b positive B cell malignancies.
- Trial name
- NCT05436509
- Testing
- bi-4SCAR CD19/79b T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Cancer
Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis
The primary objective of this study is to verify the safety of antigen-specific T cells (CAR-T) and engineered immune effector cytotoxic T cells (EIE) modified by immunoregulatory genes and immune modified dendritic cell vaccine…
- Trial name
- NCT04085159
- Testing
- Antigen-specific T cells CART/CTL and DCvac
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
ACL Injury
Andrews Return to Sport ACL Score
This project will develop a data-driven decision making model to assess a competitive athlete's readiness to return to sport after ACL injury and surgery safely.
- Trial name
- NCT05578248
- Testing
- Magnetic Resonance Imaging (MRI), ACL reconstruction
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Andrews Research & Education Foundation
Allogeneic Stem Cell Transplantation
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
Bloodstream infections (BSI) caused by bacteria translocating across injured oral mucosa are a significant cause of morbidity and mortality in patients undergoing stem cell transplantation (SCT).
- Trial name
- NCT05579639
- Testing
- Xylitol
- Where
- 3 sites in United States
- Volunteers
- 256 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Acute Myeloid Leukemia
Multiple CAR-T Cell Therapy Targeting AML
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple CAR T-cell therapy which combines CAR T cells against CLL-1 with CAR T cells targeting CD123 or CD33 in patients with relapsed and…
- Trial name
- NCT04010877
- Testing
- CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
CD19 Negative B-cell Malignancies
4SCAR-T Therapy Post CD19-targeted Immunotherapy
This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells (4SCAR-T) targeting CD19-negative B-ALL that express alternative surface antigens such as CD22, CD10…
- Trial name
- NCT04430530
- Testing
- Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Malignant Disease
GD2/CD56 Bi-specific CAR-T Cell Therapy
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of anti-GD2/CD56 bi-specific CAR-T cell therapy in patients with GD2 and/or CD56 positive cancer.
- Trial name
- NCT05437328
- Testing
- bi-4SCAR GD2/CD56 T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Pathogen Infection, EBV Infection
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
Epstein Barr Virus (EBV) or Cytomegalovirus (CMV) infection results in significant morbidity and mortality in hematopoietic stem cell transplantation (HSCT) patients.
- Conditions
- Pathogen Infection, EBV Infection, CMV Infection, Adenovirus Infection
- Trial name
- NCT03159364
- Testing
- pathogen-specific CTLs
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
B-Cell Acute Lymphoblastic Leukemia
NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
The purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of B-cell acute lymphoblastic leukemia (B-ALL) based on multi-antigen-targeted chimeric antigen receptor T…
- Trial name
- NCT05262673
- Testing
- Antigen-specific T cells CART/CTL and DCvac
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Amblyopia
Evaluation of AmblyoFix for the Treatment of Unilateral Amblyopia
This is a prospective, randomized, parallel-group, assessor-masked, non-inferiority clinical trial designed to compare the efficacy, safety, and adherence of AmblyoFix binocular digital therapy with standard occlusion (patching)…
- Trial name
- NCT07240311
- Testing
- AmblyoFix binocular digital therapy, Occlusion therapy (Patching)
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Eyesight Electronics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.